**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 58638

**Manuscript Type:** MINIREVIEWS

**Effects of ketogenic diet and ketone bodies on the cardiovascular system: Concentration matters**

Nasser S *et al*. Ketone bodies and the cardiovascular system

Souad Nasser, Varvara Vialichka, Marta Biesiekierska, Aneta Balcerczyk, Luciano Pirola

**Souad Nasser, Luciano Pirola,** Carmen Laboratory, INSERM Unit 1060—Lyon 1 University, Pierre Benite 69310, France

**Varvara Vialichka, Marta Biesiekierska, Aneta Balcerczyk,** Faculty of Biology and Environmental Protection, Department of Molecular Biophysics, University of Lodz, Lodz 90-236, Poland

**Varvara Vialichka,** **The** **University of Lodz Doctoral School of Exact and Natural Sciences,** Lodz 90-237, Poland

**Author contributions:** All authors contributed to the writing of the manuscript; Pirola L and Balcerczyk A supervised the project and generated the final version of the paper.

**Supported by** Polish National Science Centre, Project Grant NCN Harmonia, No. 2019/30/M/NZ3/00682; and NAWA/Campusfrance Polonium, No. PPN/X/RJ/1876/2019.

**Corresponding author: Luciano Pirola, PhD, Senior Scientist,** Carmen Laboratory, INSERM Unit 1060—Lyon 1 University, South Lyon Medical Faculty Sector 2, CENS ELI-2D Building, 165 Chemin du Grand Revoyet, Pierre Benite 69310, France. luciano.pirola@univ-lyon1.fr

**Received:** August 3, 2020

**Revised:** September 29, 2020

**Accepted:** October 19, 2020

**Published online:** December 15, 2020

**Abstract**

Ketone bodies have emerged as central mediators of metabolic health, and multiple beneficial effects of a ketogenic diet, impacting metabolism, neuronal pathologies and, to a certain extent, tumorigenesis, have been reported both in animal models and clinical research. Ketone bodies, endogenously produced by the liver, act pleiotropically as metabolic intermediates, signaling molecules, and epigenetic modifiers. The endothelium and the vascular system are central regulators of the organism’s metabolic state and become dysfunctional in cardiovascular disease, atherosclerosis, and diabetic micro- and macrovascular complications. As physiological circulating ketone bodies can attain millimolar concentrations, the endothelium is the first-line cell lineage exposed to them. While in diabetic ketoacidosis high ketone body concentrations are detrimental to the vasculature, recent research revealed that ketone bodies in the low millimolar range may exert beneficial effects on endothelial cell (EC) functioning by modulating the EC inflammatory status, senescence, and metabolism. Here, we review the long-held evidence of detrimental cardiovascular effects of ketoacidosis as well as the more recent evidence for a positive impact of ketone bodies—at lower concentrations—on the ECs metabolism and vascular physiology and the subjacent cellular and molecular mechanisms. We also explore arising controversies in the field and discuss the importance of ketone body concentrations in relation to their effects. At low concentration, endogenously produced ketone bodies upon uptake of a ketogenic diet or supplemented ketone bodies (or their precursors) may prove beneficial to ameliorate endothelial function and, consequently, pathologies in which endothelial damage occurs.

**Key Words:** Endothelial cells; Ketone bodies; Vascular physiology; β-Hydroxybutyrate; β-Hydroxybutyrylation; Histone post-translational modifications

**Citation:** Nasser S, Vialichka V, Biesiekierska M, Balcerczyk A, Pirola L. Effects of ketogenic diet and ketone bodies on the cardiovascular system: Concentration matters. *World J Diabetes* 2020; 11(12): 584-595

**URL:** <https://www.wjgnet.com/1948-9358/full/v11/i12/584.htm>

**DOI:** https://dx.doi.org/10.4239/wjd.v11.i12.584

**Core Tip:** Ketone bodies, acting as fuel molecules, signaling molecules, and epigenetic regulators, improve metabolic health and lifespan. The endothelium and the vascular system are central regulators of the organism’s metabolic state and become dysfunctional in cardiovascular disease and diabetic complications. While in diabetic ketoacidosis high ketone bodies concentrations are detrimental to the vasculature, ketone bodies in the low millimolar range may exert beneficial effects on the vascular system. At low concentrations, ketone bodies may prove beneficial to ameliorate vascular function and alleviate cardiovascular disease.

**INTRODUCTION**

Ketogenesis, consisting of the production by perivenous hepatocytes of the ketone bodies β-hydroxybutyrate (BHB) and acetoacetate (AcAc) using fatty acid-derived acetyl CoA, is a physiologically important process to produce an alternative metabolic source of energy to glucose during the neonatal period, starvation, or prolonged physical effort (figure with ketogenesis pathway in hepatocyte mitochondria). Spontaneous decarboxylation of AcAc yields acetone, the third and quantitatively minor ketone body[1].

The biosynthesis of ketone bodies is connected to multiple metabolic pathways, including the tricarboxylic acid cycle, β-oxidation of fatty acids, de novo lipogenesis, sterol biosynthesis, glucose metabolism, and the mitochondrial electron transport chain. Moreover, hormonal signaling and intracellular signal transduction pathways are also affected by ketone bodies.

In extrahepatic tissues, AcAc- and BHB-derived AcAc serve as a substrate to produce AcAc-CoA *via* the enzymatic activity of succinyl-CoA:3-oxoacid-CoA transferase (coded by the gene *OXCT1*)[1]. In turn, AcAc-CoA generates two molecules of AcCoA. The metabolic necessity of physiological ketogenesis is highlighted by the fact that whole-body *OXCT1* gene ablation induces postnatal mortality in mice[2]. BHB is the most abundant ketone body and has been reported to serve as an alternative energy source for the heart in diabetic patients[3] and to be slightly elevated in diabetic patients treated with the sodium-glucose co-transporter 2 inhibitor dapagliflozin, with this low-ketonemic state being correlated to improved insulin sensitivity[4].

On the other hand, diabetic ketoacidosis, in which concentrations of ketone bodies are extremely high, is a serious complication of diabetes mellitus, whereby serum concentrations of ketone bodies attain high levels and serve as nutriment to compensate for the organ’s failure to utilize glucose[4]. Therefore, ketone bodies can be either a necessary nutrient or the reflection of a pathological status depending on their plasmatic concentration.

The understanding of the physiological role(s) of ketone bodies, and in particular BHB, recently took an unexpected turn when it was demonstrated that BHB acts as a histone deacetylase inhibitor, thereby favoring histone hyperacetylation. Such histone hyperacetylation has been associated with the antioxidant properties of BHB in a mouse model[5]. At approximately the same time, BHB has been proposed to act as an anti-inflammatory molecule by targeting the inflammasome[6]. In addition, a novel histone post-translational modification (PTM) termed β-hydroxybutyrylation, which consists of the formation of an amide bond between the BHB carboxyl group and the histone lysine ε amino group, has been reported. This discovery expanded the repertoire of histone PTMs and identified BHB as a molecule involved in epigenetic control of transcription[7].

Earlier studies analyzed the genome-wide histone 3 lysine 9 and lysine 14 (H3K9/K14) hyperacetylation and DNA methylation in response to elevated glucose concentrations in primary human vascular cells. Therein, a number of specific hyperacetylation and CpG methylation signatures associated with the transcriptional upregulation of genes involved in metabolic and cardiovascular disease were identified[8]. Chronic exposure of vascular endothelial cells (ECs) to high glucose concentrations: (1) recapitulated hyperglycemia-mediated induction of gene ontology classes and cellular pathways *via* the modulation of acetylated H3K9/K14 in multiple genomic loci[9]; and (2) induced the upregulation of several proinflammatory and proatherosclerotic genes[8]. These initial observations linking prolonged exposure of ECs to high-glucose media and epigenetic alterations have been validated in clinical samples (circulating blood mononuclear cells) from participants in the DCCT/EDIC trial[10].

Collectively, these data hint at the possibility that the endothelium may be amenable to pharmacological interventions targeting the epigenome to reverse epigenetic changes occurring in diabetic endothelial dysfunction and diabetes-induced endothelial proliferation[11]. Given that the endothelium is the first-line tissue exposed to circulating ketone bodies and considering that BHB has been shown to purport/support/mediate anti-inflammatory and antioxidative features, a strong interest has been directed in the last few years towards understanding the effect of BHB on the physiology of ECs. We review here the evidence indicating that ketone bodies, and in particular BHB, at low concentrations potentially contribute to ameliorating endothelial and vascular function in metabolic disease, while elevated concentrations of ketone bodies as observed in diabetic ketoacidosis contribute to the diabetic vasculopathy and diabetic vascular complications (Figure 1).

**Detrimental vascular effects of high ketone bodies and BHB concentrations in diabetic ketoacidosis**

The morbidity and mortality burden of type 1 diabetes (T1D) can be largely attributed to vascular inflammation and cardiovascular disease (CVD) that are promoted by the installment of a chronic inflammatory state of the endothelium[12]. Furthermore, diabetic patients experiencing frequent episodes of diabetic ketoacidosis have an increased incidence of morbidity and mortality due to vascular complications and cerebral edema[13,14]. In T1D, concentrations of ketone bodies can reach 25 mmol/L[4], as compared to low millimolar concentrations (< 7 mmol/L) induced by prolonged starving on obese volunteers[15] or during postexercise ketosis[16].

Cerebral edema is the most serious complication linked to diabetic ketoacidosis and is the first cause of mortality in type 1 diabetic children[17]. Pharmacological studies demonstrated that activation of the Na-K-Cl cotransporter expressed in the ECs of the blood-brain barrier and astrocytes mediates cerebral edema formation and inhibition of the cotransporter by bumetanide reduced edema formation in the cerebral artery occlusion models of stroke in rats. In this study, in which diabetic ketoacidosis was induced by streptozotocin and BHB and reached 3.7 mmol/(Lol·L), bumetanide efficiently reduced cerebral edema formation[18]. Furthermore, in cultured bovine cerebral microvascular ECs, both AcAc and BHB stimulated the activity of the Na-K-Cl cotransporter[18].

In a model of traumatic brain injury in rats, affecting the blood-brain barrier (BBB) integrity, BHB did not display a protective effect and, furthermore, caused a slight damage in the BBB integrity in healthy animals infused with BHB[19].

**Low dose BHB protects the endothelium from cell senescence**

Cellular senescence is a process that results from a variety of stress and with time leads to a state of irreversible growth cessation. Senescent cells accumulate during aging and have been involved in the promotion of various age-related diseases. Cellular senescence can play an important role in tumor suppression, wound healing, and tissue fibrosis protection. However, there is also growing evidence that senescent cells can cause adverse effects *in vivo* and contribute to tissue remodeling, aging of the body, and vascular diseases associated with inflammation and dysfunction of ECs and smooth muscles[20,21]. Although many studies have focused on the beneficial effects of calorie restriction, which can prolong life and delay aging in various species[22], the effect and mechanism of ketone bodies on the quiescence of vascular cells and senescence have been less investigated[20,23]. An early study indicated that BHB supplementation extends the lifespan of *Caenorhabditis elegans* by 20% through the DAF-16/FOXO and SKN-1/Nrf pathways[24]. In mammals, BHB decreases the secretory phenotype associated with senescence and vascular cell senescence[25]. In addition, the ketogenic diet (KD) significantly extended the median lifespan of mice and preserved the physical function of older mice[26].

Treatment of human umbilical vein ECs (HUVEC) and human aortic smooth muscle cells treated with BHB suppressed oxidant-induced elevation of senescence markers. ΒHB has been shown to prevent both replicative and stress-induced senescence in vascular cells and to reduce *in vivo* serum levels of the interleukin-1α prosenescence marker. Indeed, senescence by BHB is dependent on Oct4A and independent of p53. ΒHB is involved in Oct4A elevation by direct binding to heterogeneous ribonuclear particle A1 (hnRNP A1), which induces quiescence of vascular cells and thus prevents cell senescence.

As aging is one of the major risk factors for cardiovascular disease, delaying or preventing vascular aging can protect against cardiovascular dysfunction. Caloric restriction induced the production of ketones that delay vascular aging by preventing both replication and stress that induce senescence of vascular cells. This prevention of senescence by BHB is done through its direct binding of hnRNP A1 resulting in the stabilization of the mRNA of Oct4A and the expression of Oct4A. Targeting of Oct4A by BHB or BHB-like compounds appears to be effective in preventing or delaying the progression of EC senescence. BHB has an important role in the positive regulation of Oct4A in the vascular system, which provides a new strategy to prevent vascular aging associated with senescence by accumulating or maintaining vascular cells at rest[27].

**Ketogenic diet and low BHB levels positively affect cardiovascular function**

Obesity is a predisposing factor to cardiovascular pathologies including coronary heart disease and hypertension[28,29]. As a KD could decrease body weight, indirect beneficial effects on the cardiovascular function may ensue. In a 1-year multicenter clinical study aimed at body weight (BW) reduction through a very low carbohydrate KD, BW reduction at 4 wk was 7 kg, and at week 12 was 5 kg; a reduction that was maintained until the end of the study period. At weeks 4 and 12, body fat was reduced by 3.8% and 3.4%, respectively[30]. After a 4-wk nutritional trial consisting of a KD supplemented with n-3 polyunsaturated fatty acids on overweight but otherwise healthy subjects, total body weight was reduced by an average of 4.70 kg, and body fat was reduced by 5.41 kg. In parallel, a decrease of glucose (-18.2 mg/L), total cholesterol (-16 mg/L), triglyceride (-40.5 mg/L), and low-density lipoprotein cholesterol (-9.8 mg/L) was observed in blood samples[31]. In another 6-mo study, KD, while not lowering the levels of total cholesterol, induced a shift from small and dense low-density lipoprotein to large and buoyant low-density lipoprotein, which is associated with a lowering of cardiovascular disease risk[32].

KD has an impact on the synthesis of endogenous cholesterol. 3-hydroxy3-methylglutaryl–CoA reductase 2, an enzyme transcriptionally promoted by insulin, leads to the synthesis of β-hydroxy-β-methylglutaryl-CoA, which is a precursor for hepatic ketone body production as well as endogenous cholesterol synthesis[33]. Saturated fatty acids, which promote CVD, decreased in plasma after administration of a low-carbohydrate diet[34]. Volek *et al*[35] showed that women are more sensitive to a KD because they have a more significant increase of HDL than men. However, upon administration of a KD, levels of fasting triglycerides are decreased in both sexes[36].

KD has also been shown to exert some effect on changes in blood pressure. A 48-wk study reported an improvement in systolic and diastolic blood pressure in overweight participants on a KD compared to a control group on a low-fat diet with the addition of orlistat[37]. Decreased systolic blood pressure was observed after 3-mo of a KD, and the decrease persisted even after a year[30]. As a decrease of systolic blood pressure and diastolic blood pressure is also occurring upon a weight loss of 5%[38], a convergence between body weight loss, KD, and blood pressure can be hypothesized.

**Epigenetic alterations induced by ketone bodies in the cardiovascular system**

Epigenetics is the field of study about persistent or inherited changes in phenotypes and gene expression without any change in the DNA sequence. Epigenetic mechanisms to control gene expression involve methylation of DNA, histone PTMs, and noncoding RNAs.

***Methylation of DNA***

Several epigenome-wide association studies led to the identification of several loci potentially associated with the development of incident CVD[39]. By analyzing DNA methylation data from three independent cohorts, a methylation-based risk score associated to CVD could be defined, suggesting that CVD-specific DNA methylation patterns may identify subjects at-risk for CVD[40]. Similarly, a global decrease in DNA methylation was observed in the blood of patients with essential hypertension[41]. In atherosclerosis, global hypomethylation of DNA was observed in mouse, rabbit, and human atherosclerotic lesions[39]. DNA hypomethylation could thus mediate an expanded transcriptional activity and activation of vascular cell proliferation[42]. A decrease of the DNA methylation in CVD may also affect the inflammatory functions of leukocytes, which correlate with CV risk *via* the modulation of adhesion and migration molecules as well as soluble molecules[43]. At present, however, it is unclear whether ketone bodies affect DNA methylation patterns to control cardiovascular function (Figure 2).

***Histone PTMs***

β-hydroxybutyrate is reportedly an endogenous inhibitor of class I histone deacetylases[5]. Furthermore, BHB induces a novel histone PTM, lysine β-hydroxybutyrylation, that was identified as a new type of histone mark on multiple lysine residues of histones H1, H2A, and H3. Increased histone 3 lysine 9 β-hydroxybutyrylation levels led to the upregulation of starvation-responsive genes[7]. β-hydroxybutyrylation was also shown to occur on lysine residues on p53, simultaneously affecting p53 acetylation[44]. When directly tested on human microvascular ECs (HMEC-1), BHB administration did not increase histone acetylation, while increasing histone lysine β-hydroxybutyrylation, and BHB administration to crude nuclear extracts did not inhibit histone deacetylases catalytic activity[45]. Overall, these results further support the notion that BHB induces β-hydroxybutyrylation while producing negligible changes in the acetylation patterns[7] (Figure 2).

***miRNA***

In a study in human volunteers, miRNA expression profiles after a 6-wk regimen on a KD was significantly different from baseline and displayed sex-specific differences. In females, overexpression of miR-148, miR-26, miR-30, miR-502, miR-520, miR-548, miR-590, and miR-644 were observed, while in males the increment was amongst the following miRNAs: miR-30, miR-502, miR-548, miR-590, and miR-644. Overall, the volunteers on a KD displayed regulation of miRNAs targeting specific genes linked to nutrient metabolism as well as mTOR, PPARs, insulin, and cytokine signaling pathways[46].

Interestingly, only 18 miRNA families constitute up to 90% of the cardiac miRNAs pool, with miR-1 being the most expressed miRNA in cardiomyocytes. Together with miR-1, miR-133 (its expression is lower) generates from the same bicistronic transcript. miR-1 and miR-133 jointly promote mesoderm differentiation in embryonic stem cells. In later development, miR-1 favors and mi-R133 inhibits the differentiation of the mesoderm into cardiomyocytes. Cardiogenesis is influenced by miR-1 through the control of transcriptional factors Irx5 and Hand2, with the latter contributing to the development of the right ventricle[47] (Figure 2).

**The effects of BHB on the inflammatory status of the endothelium are dose-dependent**

Inflammation is a major driving mechanism for the development of vascular complications related to atherosclerosis and diabetes. Hyperketonemia can contribute to establishing an inflammatory environment in the EC layer and circulating monocytes. The secretion of cytokines and chemokines generates a gradient favoring the migration of the monocytes at the endothelium and promotes the adhesion of monocytes to the EC layer. Thus, hyperketonemia contributes to the inflammatory state that potentiates the adhesion of monocytes to ECs and by inducing endothelial dysfunction amplifies the risk of CVD in diabetes.

*In vitro* experiments demonstrated that BHB and AcAc at concentrations up to 10 mmol/(Lol·L) induced adhesion of the monocyte cell lines THP-1 and U937 as well as of isolated human monocytes to HUVEC cells by induction of endothelial intercellular-1 adhesion molecule (ICAM-1) and lymphocyte function-associated antigen-1 in monocytes[48]. In addition, AcAc induced an increase in monocyte chemotactic protein-1 and interleukin-8 secretion in both HUVEC cells and THP-1 and U937 monocytes[48]. AcAc, but not BHB, also induced overexpression of ICAM-1 in human brain microvascular ECs[49].

According to a study by Kanikarla-Marie *et al*[50], high ketone levels can positively regulate NOX4, leading to an increase in reactive oxygen species in HUVEC. This increase was much greater when ketone bodies were coadministered to a high-glucose containing medium. ICAM-1 is a cell surface glycoprotein expressed on cells, and the induction of ICAM-1 promotes the recruitment of monocytes/macrophages allowing macrophages to adhere. ICAM-1 levels are predictors of endothelial dysfunction and are elevated in patients with type 1 diabetes. Reactive oxygen species (ROS) derived from NADPH oxidase play a physiological role in the regulation of endothelial function and the inflammation underlying the vascular remodeling of diabetes. Various isoforms of NADPH oxidase (NOX) have now been identified and characterized as having an important function in the mediation of oxidative stress and thus the regulation of cellular functions. Several reports indicated that NOX contributes to oxidative stress in diabetes. It was also proven that activation of these enzymes can be caused by various stimuli such as cytokines, growth factors, hyperglycemia, and lipids. A high level of glucose is known to activate NOX.

Indeed, NOX4 upregulation causes an increase in ROS, which can activate various signaling pathways leading to ICAM-1 overexpression and increased adhesion of monocytes to ECs, a surrogate biomarker for vascular dysfunction. The expression of ICAM-1 on the endothelial surface plays an essential role because it facilitates recruitment, attachment, and intravasation of monocytes, which can lead to initiation and progression of plaque formation in the walls of vessels contributing to the development of atherosclerosis. The adhesion between monocytes and ECs increased in response to both AcAc and BHB. It has been shown that several markers of vascular inflammation are influenced by the presence of hyperketonemia, which can influence the progression of CVD in diabetes by increasing monocyte adherence to ECs.

Cardiovascular disease consists of a number of different diseases that affect the heart and blood vessels, most of which have similar causes, mechanisms, and treatments. Atherogenesis is a common denominator of most vascular diseases, and it is well-recognized that inflammation is the driving force behind this process. In this context, the anti-inflammatory action of a low concentration of ketone bodies may help alleviate the inflammatory burden occurring in the vasculature of individuals with CVD (Figure 3).

**The influence of ketone bodies on the myocardium**

Cardiomyocytes are structural units of the heart that similarly to oxidative skeletal muscle have a high density of mitochondria. With such an abundance of mitochondria, the myocardium is capable of oxidizing various substrates to produce ATP. Acetyl-CoA from glucose (*via* glycolysis) or lipids (*via* β-oxidation) enters the Krebs cycle. Ketone bodies, generated by the liver, also constitute major acetyl-CoA precursors for the heart[51].

As ketone bodies are not able to complement the intermediates of the Krebs cycle, these intermediates are constantly lost. Thus ketone body oxidation is cataplerotic as it leads to depletion of the Krebs cycle intermediates and impairment of the metabolic efficiency[16]. This cataplerotic effect must be balanced by anaplerotic substances such as circulating glucose, glycogen, or glucogenic amino providing pyruvate[51] with heart pyruvate carboxylase being the key anaplerotic enzyme in the heart[52].

BHB, as the quantitatively major ketone body, has been studied on myocardial tissue from patients with severe heart failure (HF) resulting in increased myocardial utilization in these patients[53]. Nielsen *et al*[54] demonstrated that BHB infusion in patients with HF reduced the ejection fraction and improved cardiac output by 2.0 L/min and left ventricular ejection fraction by 8%, simultaneously reducing systemic vascular resistance by 30% in comparison to placebo infusion. The observed effect was dose-dependent and reached significant hemodynamic effects at a circulating BHB concentration in the physiological range and exerted a beneficial hemodynamic effect on control healthy volunteers.

Early studies demonstrated that the isolated perfused rat heart at high concentrations of BHB resulted in decreased cardiac output when ketone bodies were administrated as the sole energy substrate, and the addition of glucose to the perfusate reversed this detrimental effect[55]. In accordance to these data, the coadministration of BHB (4 mmol/L) and glucose increased cardiac work[56] and cardiac output in comparison to glucose alone in an isolated rat heart model[57]. However, pathological remodeling and cardiac dysfunction in HF has been observed as a result of a heart-specific knock-out of Oxct-1, the gene responsible for control of flux through the enzymes of cardiac ketone metabolism[58]. This suggested a crucial role for sustained ketone oxidation in HF[59]. Hence, increased myocardial ketone utilization has been demonstrated in explanted hearts from patients with severe HF[53]. Collectively, these data indicated that circulating ketone bodies derived from a KD may improve myocardium functioning and can contribute to the treatment of patients with impaired functions of the cardiovascular system.

Diabetic patients suffering from HF have been observed to have an increased cardiac uptake of ketone bodies as compared to those without diabetes[3]. Chronic insulin resistance in the diabetic heart results in alterations of fuel availability and change of affinity and utilization abilities of myocytes for different substrates[60] with free fatty acids becoming the preferred substrate, which leads to significant reduction of energy efficiency and accumulation of toxic byproducts that exacerbate HF and insulin resistance[61]. Mizuno *et al*[3] demonstrated that in diabetic HF the uptake of total ketone bodies and BHB is higher in comparison to nondiabetic HF. This suggests that ketone bodies serve as a partial energy source replacement in the human diabetic heart.

**CONCLUSION**

As discussed in this review, the cardiovascular effects of ketone bodies are context-dependent and concentration-dependent (Figure 4). It is clear and undisputed because for decades the high concentrations of ketone bodies attained in diabetic ketoacidosis have severe detrimental vascular effects, worsening the morbidity and mortality of diabetic patients. On the contrary, it has emerged in more recent years that lower concentrations of circulating ketone bodies, following dietary restriction, physical effort or a medically controlled KD can exert beneficial effects on the endothelium and the cardiovascular system. The circulating concentrations of ketone bodies are of primary importance on determining the final physiological effects on the cardiovascular system.

**REFERENCES**

1 **Puchalska P**, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. *Cell Metab* 2017; **25**: 262-284 [PMID: 28178565 DOI: 10.1016/j.cmet.2016.12.022]

2 **Cotter DG**, Schugar RC, Wentz AE, d'Avignon DA, Crawford PA. Successful adaptation to ketosis by mice with tissue-specific deficiency of ketone body oxidation. *Am J Physiol Endocrinol Metab* 2013; **304**: E363-E374 [PMID: 23233542 DOI: 10.1152/ajpendo.00547.2012]

3 **Mizuno Y**, Harada E, Nakagawa H, Morikawa Y, Shono M, Kugimiya F, Yoshimura M, Yasue H. The diabetic heart utilizes ketone bodies as an energy source. *Metabolism* 2017; **77**: 65-72 [PMID: 29132539 DOI: 10.1016/j.metabol.2017.08.005]

4 **Laffel L**. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. *Diabetes Metab Res Rev* 1999; **15**: 412-426 [PMID: 10634967 DOI: 10.1002/(sici)1520-7560(199911/12)15:6<412::aid-dmrr72>3.0.co;2-8]

5 **Shimazu T**, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. *Science* 2013; **339**: 211-214 [PMID: 23223453 DOI: 10.1126/science.1227166]

6 **Youm YH**, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nat Med* 2015; **21**: 263-269 [PMID: 25686106 DOI: 10.1038/nm.3804]

7 **Xie Z**, Zhang D, Chung D, Tang Z, Huang H, Dai L, Qi S, Li J, Colak G, Chen Y, Xia C, Peng C, Ruan H, Kirkey M, Wang D, Jensen LM, Kwon OK, Lee S, Pletcher SD, Tan M, Lombard DB, White KP, Zhao H, Li J, Roeder RG, Yang X, Zhao Y. Metabolic Regulation of Gene Expression by Histone Lysine β-Hydroxybutyrylation. *Mol Cell* 2016; **62**: 194-206 [PMID: 27105115 DOI: 10.1016/j.molcel.2016.03.036]

8 **Pirola L**, Balcerczyk A, Tothill RW, Haviv I, Kaspi A, Lunke S, Ziemann M, Karagiannis T, Tonna S, Kowalczyk A, Beresford-Smith B, Macintyre G, Kelong M, Hongyu Z, Zhu J, El-Osta A. Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. *Genome Res* 2011; **21**: 1601-1615 [PMID: 21890681 DOI: 10.1101/gr.116095.110]

9 **Rafehi H**, Balcerczyk A, Lunke S, Kaspi A, Ziemann M, Kn H, Okabe J, Khurana I, Ooi J, Khan AW, Du XJ, Chang L, Haviv I, Keating ST, Karagiannis TC, El-Osta A. Vascular histone deacetylation by pharmacological HDAC inhibition. *Genome Res* 2014; **24**: 1271-1284 [PMID: 24732587 DOI: 10.1101/gr.168781.113]

10 **Miao F**, Chen Z, Genuth S, Paterson A, Zhang L, Wu X, Li SM, Cleary P, Riggs A, Harlan DM, Lorenzi G, Kolterman O, Sun W, Lachin JM, Natarajan R; DCCT/EDIC Research Group. Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. *Diabetes* 2014; **63**: 1748-1762 [PMID: 24458354 DOI: 10.2337/db13-1251]

11 **Wojtala M**, Pirola L, Balcerczyk A. Modulation of the vascular endothelium functioning by dietary components, the role of epigenetics. *Biofactors* 2017; **43**: 5-16 [PMID: 27355807 DOI: 10.1002/biof.1306]

12 **Devaraj S**, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. *Diabetes* 2007; **56**: 2790-2796 [PMID: 17686944 DOI: 10.2337/db07-0784]

13 **White NH**. Diabetic ketoacidosis in children. *Endocrinol Metab Clin North Am* 2000; **29**: 657-682 [PMID: 11149156 DOI: 10.1016/s0889-8529(05)70158-4]

14 **Bialo SR**, Agrawal S, Boney CM, Quintos JB. Rare complications of pediatric diabetic ketoacidosis. *World J Diabetes* 2015; **6**: 167-174 [PMID: 25685287 DOI: 10.4239/wjd.v6.i1.167]

15 **Owen OE**, Felig P, Morgan AP, Wahren J, Cahill GF Jr. Liver and kidney metabolism during prolonged starvation. *J Clin Invest* 1969; **48**: 574-583 [PMID: 5773093 DOI: 10.1172/JCI106016]

16 **Koeslag JH**, Noakes TD, Sloan AW. Post-exercise ketosis. *J Physiol* 1980; **301**: 79-90 [PMID: 6997456 DOI: 10.1113/jphysiol.1980.sp013190]

17 **Edge JA**, Ford-Adams ME, Dunger DB. Causes of death in children with insulin dependent diabetes 1990-96. *Arch Dis Child* 1999; **81**: 318-323 [PMID: 10490436 DOI: 10.1136/adc.81.4.318]

18 **Lam TI**, Anderson SE, Glaser N, O'Donnell ME. Bumetanide reduces cerebral edema formation in rats with diabetic ketoacidosis. *Diabetes* 2005; **54**: 510-516 [PMID: 15677509 DOI: 10.2337/diabetes.54.2.510]

19 **Orhan N**, Ugur Yilmaz C, Ekizoglu O, Ahishali B, Kucuk M, Arican N, Elmas I, Gürses C, Kaya M. Effects of beta-hydroxybutyrate on brain vascular permeability in rats with traumatic brain injury. *Brain Res* 2016; **1631**: 113-126 [PMID: 26656066 DOI: 10.1016/j.brainres.2015.11.038]

20 **Minamino T**, Komuro I. Vascular cell senescence: contribution to atherosclerosis. *Circ Res* 2007; **100**: 15-26 [PMID: 17204661 DOI: 10.1161/01.RES.0000256837.40544.4a]

21 **Kovacic JC**, Moreno P, Hachinski V, Nabel EG, Fuster V. Cellular senescence, vascular disease, and aging: Part 1 of a 2-part review. *Circulation* 2011; **123**: 1650-1660 [PMID: 21502583 DOI: 10.1161/CIRCULATIONAHA.110.007021]

22 **Colman RJ**, Beasley TM, Kemnitz JW, Johnson SC, Weindruch R, Anderson RM. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. *Nat Commun* 2014; **5**: 3557 [PMID: 24691430 DOI: 10.1038/ncomms4557]

23 **Uryga AK**, Bennett MR. Ageing induced vascular smooth muscle cell senescence in atherosclerosis. *J Physiol* 2016; **594**: 2115-2124 [PMID: 26174609 DOI: 10.1113/JP270923]

24 **Edwards C**, Canfield J, Copes N, Rehan M, Lipps D, Bradshaw PC. D-beta-hydroxybutyrate extends lifespan in C. elegans. *Aging (Albany NY)* 2014; **6**: 621-644 [PMID: 25127866 DOI: 10.18632/aging.100683]

25 **Newman JC**, Covarrubias AJ, Zhao M, Yu X, Gut P, Ng CP, Huang Y, Haldar S, Verdin E. Ketogenic Diet Reduces Midlife Mortality and Improves Memory in Aging Mice. *Cell Metab* 2017; **26**: 547-557.e8 [PMID: 28877458 DOI: 10.1016/j.cmet.2017.08.004]

26 **Roberts MN**, Wallace MA, Tomilov AA, Zhou Z, Marcotte GR, Tran D, Perez G, Gutierrez-Casado E, Koike S, Knotts TA, Imai DM, Griffey SM, Kim K, Hagopian K, McMackin MZ, Haj FG, Baar K, Cortopassi GA, Ramsey JJ, Lopez-Dominguez JA. A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice. *Cell Metab* 2017; **26**: 539-546.e5 [PMID: 28877457 DOI: 10.1016/j.cmet.2017.08.005]

27 **Han YM**, Bedarida T, Ding Y, Somba BK, Lu Q, Wang Q, Song P, Zou MH. β-Hydroxybutyrate Prevents Vascular Senescence through hnRNP A1-Mediated Upregulation of Oct4. *Mol Cell* 2018; **71**: 1064-1078.e5 [PMID: 30197300 DOI: 10.1016/j.molcel.2018.07.036]

28 **Seravalle G**, Grassi G. Obesity and hypertension. *Pharmacol Res* 2017; **122**: 1-7 [PMID: 28532816 DOI: 10.1016/j.phrs.2017.05.013]

29 **Zheng Y**, Manson JE, Yuan C, Liang MH, Grodstein F, Stampfer MJ, Willett WC, Hu FB. Associations of Weight Gain From Early to Middle Adulthood With Major Health Outcomes Later in Life. *JAMA* 2017; **318**: 255-269 [PMID: 28719691 DOI: 10.1001/jama.2017.7092]

30 **Cicero AF**, Benelli M, Brancaleoni M, Dainelli G, Merlini D, Negri R. Middle and Long-Term Impact of a Very Low-Carbohydrate Ketogenic Diet on Cardiometabolic Factors: A Multi-Center, Cross-Sectional, Clinical Study. *High Blood Press Cardiovasc Prev* 2015; **22**: 389-394 [PMID: 25986079 DOI: 10.1007/s40292-015-0096-1]

31 **Paoli A**, Moro T, Bosco G, Bianco A, Grimaldi KA, Camporesi E, Mangar D. Effects of n-3 polyunsaturated fatty acids (ω-3) supplementation on some cardiovascular risk factors with a ketogenic Mediterranean diet. *Mar Drugs* 2015; **13**: 996-1009 [PMID: 25689563 DOI: 10.3390/md13020996]

32 **Westman EC**, Yancy WS Jr, Olsen MK, Dudley T, Guyton JR. Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses. *Int J Cardiol* 2006; **110**: 212-216 [PMID: 16297472 DOI: 10.1016/j.ijcard.2005.08.034]

33 **Paoli A**, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. *Eur J Clin Nutr* 2013; **67**: 789-796 [PMID: 23801097 DOI: 10.1038/ejcn.2013.116]

34 **Feinman RD**, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, Nielsen JV, Krarup T, Saslow L, Roth KS, Vernon MC, Volek JS, Wilshire GB, Dahlqvist A, Sundberg R, Childers A, Morrison K, Manninen AH, Dashti HM, Wood RJ, Wortman J, Worm N. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. *Nutrition* 2015; **31**: 1-13 [PMID: 25287761 DOI: 10.1016/j.nut.2014.06.011]

35 **Volek JS**, Sharman MJ, Gómez AL, DiPasquale C, Roti M, Pumerantz A, Kraemer WJ. Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial lipemic responses in overweight women. *J Am Coll Nutr* 2004; **23**: 177-184 [PMID: 15047685 DOI: 10.1080/07315724.2004.10719359]

36 **Volek JS**, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, Kraemer WJ, Bibus DM, Fernandez ML, Feinman RD. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. *Lipids* 2009; **44**: 297-309 [PMID: 19082851 DOI: 10.1007/s11745-008-3274-2]

37 **Mayer SB**, Jeffreys AS, Olsen MK, McDuffie JR, Feinglos MN, Yancy WS Jr. Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes. *Diabetes Obes Metab* 2014; **16**: 90-93 [PMID: 23911112 DOI: 10.1111/dom.12191]

38 **Kirkpatrick CF**, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE, Willard KE, Maki KC. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. *J Clin Lipidol* 2019; **13**: 689-711.e1 [PMID: 31611148 DOI: 10.1016/j.jacl.2019.08.003]

39 **Zhang Y**, Zeng C. Role of DNA methylation in cardiovascular diseases. *Clin Exp Hypertens* 2016; **38**: 261-267 [PMID: 27028400 DOI: 10.3109/10641963.2015.1107087]

40 **Westerman K**, Fernández-Sanlés A, Patil P, Sebastiani P, Jacques P, Starr JM, J Deary I, Liu Q, Liu S, Elosua R, DeMeo DL, Ordovás JM. Epigenomic Assessment of Cardiovascular Disease Risk and Interactions With Traditional Risk Metrics. *J Am Heart Assoc* 2020; **9**: e015299 [PMID: 32308120 DOI: 10.1161/JAHA.119.015299]

41 **Smolarek I**, Wyszko E, Barciszewska AM, Nowak S, Gawronska I, Jablecka A, Barciszewska MZ. Global DNA methylation changes in blood of patients with essential hypertension. *Med Sci Monit* 2010; **16**: CR149-CR155 [PMID: 20190686]

42 **Hiltunen MO**, Turunen MP, Häkkinen TP, Rutanen J, Hedman M, Mäkinen K, Turunen AM, Aalto-Setälä K, Ylä-Herttuala S. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. *Vasc Med* 2002; **7**: 5-11 [PMID: 12083735 DOI: 10.1191/1358863x02vm418oa]

43 **Baccarelli A**, Rienstra M, Benjamin EJ. Cardiovascular epigenetics: basic concepts and results from animal and human studies. *Circ Cardiovasc Genet* 2010; **3**: 567-573 [PMID: 21156932 DOI: 10.1161/CIRCGENETICS.110.958744]

44 **Liu K**, Li F, Sun Q, Lin N, Han H, You K, Tian F, Mao Z, Li T, Tong T, Geng M, Zhao Y, Gu W, Zhao W. p53 β-hydroxybutyrylation attenuates p53 activity. *Cell Death Dis* 2019; **10**: 243 [PMID: 30858356 DOI: 10.1038/s41419-019-1463-y]

45 **Chriett S**, Dąbek A, Wojtala M, Vidal H, Balcerczyk A, Pirola L. Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. *Sci Rep* 2019; **9**: 742 [PMID: 30679586 DOI: 10.1038/s41598-018-36941-9]

46 **Cannataro R**, Perri M, Gallelli L, Caroleo MC, De Sarro G, Cione E. Ketogenic Diet Acts on Body Remodeling and MicroRNAs Expression Profile. *Microrna* 2019; **8**: 116-126 [PMID: 30474543 DOI: 10.2174/2211536608666181126093903]

47 **Wojciechowska A**, Braniewska A, Kozar-Kamińska K. MicroRNA in cardiovascular biology and disease. *Adv Clin Exp Med* 2017; **26**: 865-874 [PMID: 29068585 DOI: 10.17219/acem/62915]

48 **Rains JL**, Jain SK. Hyperketonemia increases monocyte adhesion to endothelial cells and is mediated by LFA-1 expression in monocytes and ICAM-1 expression in endothelial cells. *Am J Physiol Endocrinol Metab* 2011; **301**: E298-E306 [PMID: 21540444 DOI: 10.1152/ajpendo.00038.2011]

49 **Hoffman WH**, Cheng C, Passmore GG, Carroll JE, Hess D. Acetoacetate increases expression of intercellular adhesion molecule-1 (ICAM-1) in human brain microvascular endothelial cells. *Neurosci Lett* 2002; **334**: 71-74 [PMID: 12435474 DOI: 10.1016/s0304-3940(02)00816-9]

50 **Kanikarla-Marie P**, Jain SK. Hyperketonemia (acetoacetate) upregulates NADPH oxidase 4 and elevates oxidative stress, ICAM-1, and monocyte adhesivity in endothelial cells. *Cell Physiol Biochem* 2015; **35**: 364-373 [PMID: 25591777 DOI: 10.1159/000369702]

51 **Abdul Kadir A**, Clarke K, Evans RD. Cardiac ketone body metabolism. *Biochim Biophys Acta Mol Basis Dis* 2020; **1866**: 165739 [PMID: 32084511 DOI: 10.1016/j.bbadis.2020.165739]

52 **Des Rosiers C**, Labarthe F, Lloyd SG, Chatham JC. Cardiac anaplerosis in health and disease: food for thought. *Cardiovasc Res* 2011; **90**: 210-219 [PMID: 21398307 DOI: 10.1093/cvr/cvr055]

53 **Bedi KC Jr**, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, Wang LL, Javaheri A, Blair IA, Margulies KB, Rame JE. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. *Circulation* 2016; **133**: 706-716 [PMID: 26819374 DOI: 10.1161/CIRCULATIONAHA.115.017545]

54 **Nielsen R**, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms HJ, Frøkiær J, Eiskjaer H, Jespersen NR, Mellemkjaer S, Lassen TR, Pryds K, Bøtker HE, Wiggers H. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. *Circulation* 2019; **139**: 2129-2141 [PMID: 30884964 DOI: 10.1161/CIRCULATIONAHA.118.036459]

55 **Taegtmeyer H**, Hems R, Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. *Biochem J* 1980; **186**: 701-711 [PMID: 6994712 DOI: 10.1042/bj1860701]

56 **Kashiwaya Y**, Sato K, Tsuchiya N, Thomas S, Fell DA, Veech RL, Passonneau JV. Control of glucose utilization in working perfused rat heart. *J Biol Chem* 1994; **269**: 25502-25514 [PMID: 7929251]

57 **Sato K**, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, Chance B, Clarke K, Veech RL. Insulin, ketone bodies, and mitochondrial energy transduction. *FASEB J* 1995; **9**: 651-658 [PMID: 7768357 DOI: 10.1096/fasebj.9.8.7768357]

58 **Schugar RC**, Moll AR, André d'Avignon D, Weinheimer CJ, Kovacs A, Crawford PA. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. *Mol Metab* 2014; **3**: 754-769 [PMID: 25353003 DOI: 10.1016/j.molmet.2014.07.010]

59 **Aubert G**, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP. The Failing Heart Relies on Ketone Bodies as a Fuel. *Circulation* 2016; **133**: 698-705 [PMID: 26819376 DOI: 10.1161/CIRCULATIONAHA.115.017355]

60 **Dei Cas A**, Fonarow GC, Gheorghiade M, Butler J. Concomitant diabetes mellitus and heart failure. *Curr Probl Cardiol* 2015; **40**: 7-43 [PMID: 25499908 DOI: 10.1016/j.cpcardiol.2014.09.002]

61 **Qian N**, Wang Y. Ketone body metabolism in diabetic and non-diabetic heart failure. *Heart Fail Rev* 2020; **25**: 817-822 [PMID: 31612363 DOI: 10.1007/s10741-019-09857-3]

62 **Lusardi TA**, Akula KK, Coffman SQ, Ruskin DN, Masino SA, Boison D. Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. *Neuropharmacology* 2015; **99**: 500-509 [PMID: 26256422 DOI: 10.1016/j.neuropharm.2015.08.007]

63 **Kobow K**, Kaspi A, Harikrishnan KN, Kiese K, Ziemann M, Khurana I, Fritzsche I, Hauke J, Hahnen E, Coras R, Mühlebner A, El-Osta A, Blümcke I. Deep sequencing reveals increased DNA methylation in chronic rat epilepsy. *Acta Neuropathol* 2013; **126**: 741-756 [PMID: 24005891 DOI: 10.1007/s00401-013-1168-8]

64 **Nishitani S**, Fukuhara A, Shin J, Okuno Y, Otsuki M, Shimomura I. Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in adipocytes. *Sci Rep* 2018; **8**: 8805 [PMID: 29891844 DOI: 10.1038/s41598-018-27181-y]

65 **Matsuhashi T**, Hishiki T, Zhou H, Ono T, Kaneda R, Iso T, Yamaguchi A, Endo J, Katsumata Y, Atsushi A, Yamamoto T, Shirakawa K, Yan X, Shinmura K, Suematsu M, Fukuda K, Sano M. Activation of pyruvate dehydrogenase by dichloroacetate has the potential to induce epigenetic remodeling in the heart. *J Mol Cell Cardiol* 2015; **82**: 116-124 [PMID: 25744081 DOI: 10.1016/j.yjmcc.2015.02.021]

66 **Sangalli JR**, Sampaio RV, Del Collado M, da Silveira JC, De Bem THC, Perecin F, Smith LC, Meirelles FV. Metabolic gene expression and epigenetic effects of the ketone body β-hydroxybutyrate on H3K9ac in bovine cells, oocytes and embryos. *Sci Rep* 2018; **8**: 13766 [PMID: 30214009 DOI: 10.1038/s41598-018-31822-7]

67 **Zhang X**, Cao R, Niu J, Yang S, Ma H, Zhao S, Li H. Molecular basis for hierarchical histone de-β-hydroxybutyrylation by SIRT3. *Cell Discov* 2019; **5**: 35 [PMID: 31636949 DOI: 10.1038/s41421-019-0103-0]

**Footnotes**

**Conflict-of-interest statement:** The authors have declared no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** July 31, 2020

**First decision:** September 24, 2020

**Article in press:** October 19, 2020

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** France

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0


**P-Reviewer:** de Melo FF **S-Editor:** Gao CC **L-Editor:** Filipodia **P-Editor:** Ma YJ

**Figure Legends**




**Figure 1 Concentration dependency of the biochemical and physiological responses to ketone bodies.** Low to medium concentrations of ketone bodies, attained through fasting, ketogenic diet, or physical effort, convey physiologically beneficial effects. Conversely, pathological ketone body concentrations, observed in diabetic ketoacidosis, contribute to the disease morbidity and can be life threatening. HDACs: Histone deacetylases.



**Figure 2 Schematic diagram summarizing the main epigenetic alterations induced by** β**-hydroxybutyrate or a** **ketogenic diet[7,46,62-67].** BHB: β-Hydroxybutyrate; HDACs: Histone deacetylases; KD: Ketogenic diet.

**Figure 3 *In vitro* and *in vivo* responses to ketone bodies are dependent of their concentrations, with low to moderate concentrations exerting beneficial effects on the endothelium and the cardiovascular system and high concentrations typical of diabetic ketoacidosis being detrimental.** AcAc: Acetoacetate; BHB: β-hydroxybutyrate; HUVECs: Human umbilical vein endothelial cells; ICAM-1: Intercellular-1 adhesion molecule; IL: Interleukin; KB: Ketone bodies; LFA-1: Lymphocyte function-associated antigen-1; MCP1: Monocyte chemotactic protein-1.



**Figure 4** **Summary of the physiological changes occurring upon assumption of a ketogenic diet that affects cardiovascular function.** HbA1c: Hemoglobin A1c; HDL-c: High-density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol; TG: Triglycerides.